Drug intelligence / Profile preview

Combo #1

Development stage: Preclinical
Lead developer: Oncko
Modality: Small Molecules

Overview

Combo #1 is a preclinical-stage multi-drug combination therapy being developed by Oncko for the treatment of second-line non-small cell lung cancer (2L NSCLC). The combination is designed to utilize four distinct drugs acting through orthogonal mechanisms of action to maximize therapeutic efficacy and potentially overcome resistance mechanisms common in advanced lung cancer. As of the current pipeline status, the specific molecular targets and individual drug components of the combination have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on Combo #1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combo #1.

Explore the full profile